Gilead Sciences, Inc. (NASDAQ:GILD) Stake Trimmed by Liberty One Investment Management LLC

Liberty One Investment Management LLC trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 16.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 78,953 shares of the biopharmaceutical company's stock after selling 15,009 shares during the quarter. Gilead Sciences accounts for approximately 0.9% of Liberty One Investment Management LLC's portfolio, making the stock its 25th largest holding. Liberty One Investment Management LLC's holdings in Gilead Sciences were worth $8,847,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Gilead Sciences in the first quarter valued at about $25,000. Goodman Advisory Group LLC acquired a new stake in shares of Gilead Sciences in the first quarter valued at about $29,000. Core Alternative Capital grew its stake in shares of Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 241 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC grew its stake in shares of Gilead Sciences by 158.8% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 216 shares in the last quarter. Finally, Investment Research & Advisory Group Inc. grew its stake in shares of Gilead Sciences by 33.3% in the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Analyst Ratings Changes

GILD has been the subject of a number of recent research reports. Cantor Fitzgerald initiated coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price for the company. JPMorgan Chase & Co. increased their target price on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Oppenheimer reduced their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Finally, Morgan Stanley increased their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus price target of $110.55.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the transaction, the insider directly owned 121,152 shares of the company's stock, valued at $13,026,263.04. The trade was a 18.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $110.17, for a total value of $275,425.00. Following the transaction, the chief financial officer directly owned 165,110 shares in the company, valued at approximately $18,190,168.70. The trade was a 1.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 58,500 shares of company stock valued at $6,340,745 over the last three months. Company insiders own 0.27% of the company's stock.

Gilead Sciences Stock Performance

Shares of GILD traded down $0.72 during trading hours on Tuesday, reaching $111.06. 4,682,217 shares of the company's stock traded hands, compared to its average volume of 7,691,234. The firm has a market capitalization of $138.15 billion, a price-to-earnings ratio of 23.38, a P/E/G ratio of 0.72 and a beta of 0.29. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. Gilead Sciences, Inc. has a twelve month low of $66.34 and a twelve month high of $119.96. The business's fifty day simple moving average is $107.12 and its two-hundred day simple moving average is $104.25.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The company's quarterly revenue was down .3% compared to the same quarter last year. During the same period last year, the company earned ($1.32) earnings per share. Analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.85%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's payout ratio is currently 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.